TORONTO, Sept. 12, 2022 /CNW Telbec/ – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”) (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce it has successfully launched KetaMD in Florida. KetaMD onboarded new patients and…


Previous articlePain and Psychedelics – Reviewing a Newly Published Paper
Next articleAlgernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study